145 related articles for article (PubMed ID: 17253911)
1. Outcomes of patients with prostate cancer receiving zoledronic acid or pamidronate for prevention of skeletal-related events.
Sherer JT; Adamus AT
Pharmacotherapy; 2007 Feb; 27(2):207-17. PubMed ID: 17253911
[TBL] [Abstract][Full Text] [Related]
2. The benefits of timely intervention with zoledronic acid in patients with metastatic prostate cancer to bones: a retrospective study of the US Veterans Affairs population.
Velde NV; Wu EQ; Guo A; Lu M; Yu AP; Sharma H; Liu J; Fan CP; Shi L
Prostate Cancer Prostatic Dis; 2011 Mar; 14(1):79-84. PubMed ID: 21173792
[TBL] [Abstract][Full Text] [Related]
3. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
[TBL] [Abstract][Full Text] [Related]
4. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer.
Small EJ; Smith MR; Seaman JJ; Petrone S; Kowalski MO
J Clin Oncol; 2003 Dec; 21(23):4277-84. PubMed ID: 14581438
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein MA; Coleman RE; Reitsma DJ; Chen BL; Seaman JJ
Cancer; 2003 Oct; 98(8):1735-44. PubMed ID: 14534891
[TBL] [Abstract][Full Text] [Related]
7. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group.
Rosen LS; Gordon D; Tchekmedyian S; Yanagihara R; Hirsh V; Krzakowski M; Pawlicki M; de Souza P; Zheng M; Urbanowitz G; Reitsma D; Seaman JJ
J Clin Oncol; 2003 Aug; 21(16):3150-7. PubMed ID: 12915606
[TBL] [Abstract][Full Text] [Related]
8. Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases.
Saad F; Chen YM; Gleason DM; Chin J
Clin Genitourin Cancer; 2007 Sep; 5(6):390-6. PubMed ID: 17956712
[TBL] [Abstract][Full Text] [Related]
9. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE
J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381
[TBL] [Abstract][Full Text] [Related]
10. Preserving bone health in patients with hormone-sensitive prostate cancer: the role of bisphosphonates.
Saad F; Abrahamsson PA; Miller K
BJU Int; 2009 Dec; 104(11):1573-9. PubMed ID: 20053188
[TBL] [Abstract][Full Text] [Related]
11. Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers.
Saad F; Lipton A
BJU Int; 2005 Nov; 96(7):964-9. PubMed ID: 16225510
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer.
Reed SD; Radeva JI; Glendenning GA; Saad F; Schulman KA
J Urol; 2004 Apr; 171(4):1537-42. PubMed ID: 15017215
[TBL] [Abstract][Full Text] [Related]
13. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma.
Lipton A; Zheng M; Seaman J
Cancer; 2003 Sep; 98(5):962-9. PubMed ID: 12942563
[TBL] [Abstract][Full Text] [Related]
14. Risk of skeletal-related events in patients with advanced prostate cancer treated with pamidronate or zoledronic acid.
Spence MM; Hui RL; Chan J; Schottinger JE
Ann Pharmacother; 2010 Sep; 44(9):1384-8. PubMed ID: 20682850
[TBL] [Abstract][Full Text] [Related]
15. The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid.
Oh WK; Proctor K; Nakabayashi M; Evan C; Tormey LK; Daskivich T; Antràs L; Smith M; Neary MP; Duh MS
Cancer; 2007 Mar; 109(6):1090-6. PubMed ID: 17311345
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial.
Cartenì G; Bordonaro R; Giotta F; Lorusso V; Scalone S; Vinaccia V; Rondena R; Amadori D
Oncologist; 2006; 11(7):841-8. PubMed ID: 16880243
[TBL] [Abstract][Full Text] [Related]
17. Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications.
Hirsh V; Tchekmedyian NS; Rosen LS; Zheng M; Hei YJ
Clin Lung Cancer; 2004 Nov; 6(3):170-4. PubMed ID: 15555218
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
Walter C; Al-Nawas B; Grötz KA; Thomas C; Thüroff JW; Zinser V; Gamm H; Beck J; Wagner W
Eur Urol; 2008 Nov; 54(5):1066-72. PubMed ID: 18602738
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid.
Coleman RE; Major P; Lipton A; Brown JE; Lee KA; Smith M; Saad F; Zheng M; Hei YJ; Seaman J; Cook R
J Clin Oncol; 2005 Aug; 23(22):4925-35. PubMed ID: 15983391
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: a meta-analysis of randomized clinical trials.
Machado M; Cruz LS; Tannus G; Fonseca M
Clin Ther; 2009 May; 31(5):962-79. PubMed ID: 19539097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
